Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Non-Muscle Invasive Bladder Neoplasms 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 161Specimen Handling 134enzalutamide 125Nivolumab 118Gemcitabine 96Docetaxel 92Radiosurgery 91Prednisone 81Androgen Antagonists 81Abiraterone Acetate 79Radiotherapy 75apalutamide 66Cisplatin 65darolutamide 62Ipilimumab 61Biopsy 61abiraterone 57cabozantinib 55Carboplatin 55Leuprolide 52enfortumab vedotin 50Radiation 47Pluvicto 45Standard of Care 44atezolizumab 41Surveys and Questionnaires 38acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
hydroxycamptothecinum × Genitourinary × 1 year × Clear all
NCT07424287 2026-06-02

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Not yet recruiting
236 enrolled
Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡